A triplet regimen was found to extend overall survival (OS) compared to the standard of care for patients with relapsed or refractory multiple myeloma in the phase 3 DREAMM-7 trial. The regimen consisted of belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone (BVd). Results showed improved progression-free survival (PFS) and longer duration of response in the BVd group. An interim analysis also showed a statistically significant improvement in OS. The results were deemed clinically meaningful and potentially transformative for treatment. Complete data will be presented at the ASH Annual Meeting in December.
Source link
Triplet regimen extends OS in relapsed or refractory multiple myeloma
